Nutriband (NASDAQ:NTRB) Stock Rating Lowered by Wall Street Zen

Nutriband (NASDAQ:NTRB) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Friday.

Separately, Zacks Research lowered Nutriband from a “hold” rating to a “strong sell” rating in a research report on Tuesday, September 16th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $13.00.

Nutriband Stock Performance

NASDAQ:NTRB opened at $7.26 on Friday. The stock has a market cap of $87.34 million, a P/E ratio of -2.53 and a beta of 1.13. The firm’s fifty day simple moving average is $6.96 and its 200 day simple moving average is $6.73. Nutriband has a twelve month low of $3.72 and a twelve month high of $11.78. The company has a quick ratio of 4.70, a current ratio of 4.78 and a debt-to-equity ratio of 0.01.

Nutriband (NASDAQ:NTRB) last released its quarterly earnings results on Tuesday, September 9th. The company reported ($2.12) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($1.95). The company had revenue of $0.62 million during the quarter, compared to the consensus estimate of $0.71 million. Nutriband had a negative net margin of 398.29% and a negative return on equity of 85.40%. As a group, research analysts predict that Nutriband will post -0.6 EPS for the current year.

Hedge Funds Weigh In On Nutriband

A hedge fund recently bought a new stake in Nutriband stock. Consolidated Portfolio Review Corp purchased a new position in Nutriband Inc. (NASDAQ:NTRB) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 10,350 shares of the company’s stock, valued at approximately $81,000. Consolidated Portfolio Review Corp owned about 0.09% of Nutriband at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.70% of the company’s stock.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.